Issue |
E3S Web of Conf.
Volume 488, 2024
1st International Conference on Advanced Materials & Sustainable Energy Technologies (AMSET2023)
|
|
---|---|---|
Article Number | 03021 | |
Number of page(s) | 29 | |
Section | Green Buildings; Carbon Capture & Recycling of Energy Materials | |
DOI | https://doi.org/10.1051/e3sconf/202448803021 | |
Published online | 06 February 2024 |
A review on human cancer and potential role of MXenes in cancer therapy
1 Department of Maritime Science and Technology, Faculty of Defence Science and Technology, National Defence University of Malaysia, Kuala Lumpur 57000, Malaysia
2 Department of Biological Sciences, School of Science and Technology, Sunway University, Selangor 47500, Malaysia
3 Department of science, School of Technology, Pandit Deendayal Petroleum University, Gujarat, India
* Corresponding author: nanthini@upnm.edu.my
Cancer is the second leading cause of death worldwide and is having a serious impact on the global economy. Various treatment modalities are in use to treat cancer but none of the techniques is risk-free. Recently, various nanomaterials such as gold, boron, and other compounds have been investigated for radiotherapy and as anti-cancer drug carriers with promising results. MXenes are 2D novel nanomaterials and their biomedical and anticancer properties are gaining interest due to their high biomedical activity, less bio-toxicity, and photo-responsive nature. However, the biological properties of MXense have not been studied extensively, therefore, limited data is published on its in-vitro and in-vivo anticancer activities, drug loading efficacy, targeted release, and on its photothermal therapy response. In this review, we have discussed the use of nanoparticles and MXenen nanomaterial in cancer therapy. Furthermore, the role of Mxene as a photothermal agent and drug carrier has also been emphasized, along with the present challenges for the use of nanomaterials in the treatment of cancer.
© The Authors, published by EDP Sciences, 2024
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.